drugset / Trial / NCT03432793

Drug-Drug Interaction (DDI) Study for TD-9855

NCT03432793

Phase 1 Completed 41 enrolled Theravance Biopharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.

Timeline

Start
2018-02-28
Primary completion
2018-04-21
Completion
2018-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule Oral
Subject Fluvoxamine Unknown Oral
Subject Itraconazole Small molecule Oral
Subject ampreloxetine Small molecule Oral

Indications

No indication recorded.